ENCORE: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs. crizotinib (CZ) in untreated advanced ALK+ NSCLC

M Thomas,DR Camidge,S Peters,T Mok,SM Gadgeel, P Cheema,N Pavlakis,F De Marinis, D Stroyakovskii,BC Cho, L Zhang,D Moro-Sibilot,A Zeaiter,E Mitry,B Balas,B Müller,AT Shaw

60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.Pneumologie（2019）

Cited 41|Views8

No score

Abstract

Background The primary ALEX (NCT02075840) analysis showed superior investigator (INV)-assessed progression-free survival (PFS) with ALC vs. CZ (HR 0.47, 95% CI 0.34 – 0.65, p < 0.001; median 11.1 months [m] CZ, not estimable [NE] ALC) in untreated ALK+ NSCLC. Here, we report updated data (cutoff Dec 1 2017).

Translated text

Key words

alc,alectinib

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined